Diagnostic Performance of Urinary CD163 as a Non-invasive Biomarker for Egyptian Lupus Nephritis Patients Versus Conventional Biomarkers
Key facts
- Who runs it
- Assiut University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 50 people, planned
- Started
- 1 Oct 2026
- Expected to end
- 1 Feb 2028
- Type of study
- Observational, 3 groups
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Adults aged 18 years or older
- Diagnosis of systemic lupus erythematosus (SLE) according to the 2019 ACR/EULAR classification criteria
- Diagnosis of lupus nephritis according to the ACR criteria
- Biopsy-proven lupus nephritis
- Adequate renal biopsy tissue available for histopathological classification and assessment of activity and chronicity indices
- Active lupus nephritis requiring induction or escalation of immunosuppressive treatment
- Availability of baseline laboratory investigations
- Ability to provide a urine sample for urinary soluble CD163 measurement
Who cannot take part
- Previous kidney transplantation
- Chronic kidney disease unrelated to systemic lupus erythematosus
- Recent infection or acute inflammatory condition
- Active urinary tract infection at the time of urine sampling
- Severe infection requiring hospitalization or intravenous antimicrobial treatment at baseline
- Malignancy or another major inflammatory disease that could significantly affect urinary CD163 levels
- Inadequate renal biopsy specimen for histopathological assessment
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
kidney damage. Monitoring disease activity and predicting treatment response remain challenging because conventional laboratory markers may not always accurately reflect ongoing kidney inflammation.
Read full original descriptionShow less
This prospective observational study aims to evaluate the potential of urinary soluble CD163 (uCD163) as a non-invasive biomarker for predicting renal remission in patients with lupus nephritis. The study will investigate the relationship between urinary CD163 levels, clinical and laboratory parameters, and kidney biopsy findings. Serial urinary CD163 measurements will be performed during a six-month follow-up period to assess their association with changes in disease activity and response to standard immunosuppressive treatment.
The study may help determine whether urinary CD163 can provide additional information for monitoring lupus nephritis and predicting treatment outcomes.
The 3 groups in the trial
- Group (I): 30 participants
Group (I): 30 participants with histologically proven class III, IV, V or any combination of these classes of active LN.
- Group (II): 10 patients
Group (II): 10 patients with active SLE (SLEDAI \> 6) without nephritis confirmed by the absence of albuminuria or microscopic haematuria
- Group (III): 10 patients
Group (III): 10 participants with non-active SLE (SLEDAI score \<2).
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 12 November 2026